Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma

Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma

Introduction: Patients with NRAS-mutant metastatic melanoma often have an aggressive disease requiring a fast-acting, effective therapy. The MEK inhibitor binimetinib shows an overall response rate of 15% in patients with NRAS-mutant melanoma, providing a backbone for combination strategies. Our pre...

Full description

Bibliographic Details
Main Authors:	Heike Niessner, Anna Hüsch, Corinna Kosnopfel, Matthias Meinhardt, Dana Westphal, Friedegund Meier, Bastian Schilling, Tobias Sinnberg
Format:	Article
Language:	English
Published:	MDPI AG 2023-11-01
Series:	Cancers
Subjects:	malignant melanoma cancer encorafenib binimetinib BRAF inhibitor NRAS-mutated
Online Access:	https://www.mdpi.com/2072-6694/15/23/5521

Similar Items

MEK inhibitors for the treatment of NRAS mutant melanoma
by: Sarkisian S, et al.
Published: (2018-08-01)

Severe Colitis in 2 Patients with Melanoma Treated with BRAF/MEK Inhibitors: Case Report and Literature Review
by: Chloe Wautier, et al.
Published: (2024-02-01)

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma
by: Alexander Schulz, et al.
Published: (2022-10-01)

Combination of encorafenib and binimetinib in the treatment of patients with <i>BRAF</i>-mutated advanced melanoma. Case report
by: Kristina V. Orlova, et al.
Published: (2023-05-01)

Encorafenib/binimetinib induced severe liver injury in a melanoma patient: Case report and review of literature
by: Nabin Raj Karki, et al.
Published: (2021-12-01)

Case report: Parsonage-turner syndrome in a melanoma patient treated by BRAF/MEK inhibitors after immune checkpoint inhibitors
by: Charlotte Bonnefin, et al.
Published: (2023-12-01)

NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases
by: Shin Kobayashi, et al.
Published: (2023-08-01)

Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma
by: Moltara Maja Ebert, et al.
Published: (2018-04-01)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma
by: Omid Hamid, et al.
Published: (2019-10-01)

The combination of mutations in BRAF and NRAS genes within a one tumor in patients with cutaneous melanoma
by: M. B. Aksenenko, et al.
Published: (2019-10-01)

Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma
by: Fanny Barel, et al.
Published: (2017-09-01)

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
by: Markus V. Heppt, et al.
Published: (2017-08-01)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
by: Sergiu Pasca, et al.
Published: (2019-10-01)

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
by: Aaron G. Issac, et al.
Published: (2022-06-01)

Sweet syndrome in a patient receiving encorafenib and binimetinib therapy for malignant melanoma
by: Myiah Quach, BS, et al.
Published: (2024-03-01)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
by: Aleksandra Bożyk, et al.
Published: (2021-03-01)

Many Distinct Ways Lead to Drug Resistance in <i>BRAF</i>- and <i>NRAS</i>-Mutated Melanomas
by: Jiri Vachtenheim, et al.
Published: (2021-05-01)

A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma—Application to a Pharmacokinetic Study
by: Mohamed M. Hefnawy, et al.
Published: (2022-12-01)

BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study
by: Orhun Cig TASKIN, et al.
Published: (2023-01-01)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
by: Karisa C. Schreck, et al.
Published: (2019-08-01)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
by: İvo Gökmen, et al.
Published: (2023-09-01)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
by: Clare Judith Stones, et al.
Published: (2013-05-01)

Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanoma—A Retrospective Single-Institute Study
by: Gabriella Liszkay, et al.
Published: (2021-06-01)

BRAF Inhibitors in Non-Small Cell Lung Cancer
by: Vincenzo Sforza, et al.
Published: (2022-10-01)

Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR
by: Yuki Nagakubo, et al.
Published: (2019-11-01)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic <i>BRAF</i> or <i>NRAS</i>-Mutated Melanoma Patients
by: Guillaume Herbreteau, et al.
Published: (2020-07-01)

Atypical <i>BRAF</i> and <i>NRAS</i> Mutations in Mucosal Melanoma
by: Nicolas Dumaz, et al.
Published: (2019-08-01)

Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines
by: Vikas Patel, et al.
Published: (2021-12-01)

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
by: Paweł Rogala, et al.
Published: (2022-04-01)

Efficacy of Targeted Radionuclide Therapy Using [<sup>131</sup>I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma
by: Hussein Akil, et al.
Published: (2021-03-01)

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
by: Parvez M. Lokhandwala, et al.
Published: (2019-07-01)

Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations
by: Rodney Shackelford, et al.
Published: (2014-05-01)

Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAF<sup>V600E</sup> Protein
by: Elisabetta Marini, et al.
Published: (2022-12-01)

<i>BRAF</i> Inhibitors in <i>BRAF-Mutated</i> Colorectal Cancer: A Systematic Review
by: Wajeeha Aiman, et al.
Published: (2023-12-01)

Imaging Mass Spectrometry for the Classification of Melanoma Based on <i>BRAF</i>/<i>NRAS</i> Mutational Status
by: Rita Casadonte, et al.
Published: (2023-03-01)

KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician
by: Afrăsânie Vlad-Adrian, et al.
Published: (2019-09-01)

Determination of the Prevalence of Microsatellite Instability, <i>BRAF</i> and <i>KRAS</i>/<i>NRAS</i> Mutation Status in Patients with Colorectal Cancer in Slovakia
by: Tomas Rendek, et al.
Published: (2024-03-01)

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report
by: Manuel Croix, et al.
Published: (2023-08-01)

A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation
by: Mohamed W. Attwa, et al.
Published: (2021-05-01)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
by: Qiwei Yang, et al.
Published: (2018-10-01)